[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"blood-pressure-management\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:blood-pressure-management":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,78,108,143],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100643525","dry-weight-reduction-intervention-via-extra-ultrafiltration-100643525",false,"NCT07637110","Dry Weight Reduction Intervention Via Extra Ultrafiltration","DRIVE-UF","Inclusion Criteria:\n\n* Receiving thrice weekly in-center hemodialysis treatments for end stage kidney disease for at least four weeks and clinical suspicion of volume excess based on either:\n\n  1. Persistent hypertension defined by three consecutive pre-dialysis systolic blood pressures ≥140 mmHg or three consecutive pre-dialysis systolic blood pressures 130-140 mmHg plus use of at least two anti-hypertensive medications that can be tapered.\n\n     OR\n  2. Symptoms of congestion defined by a 12-item Kidney Modified Kansas City Cardiomyopathy Questionnaire (KM-KCCQ) score \\\u003C75.\n\n     Exclusion Criteria:\n* Age \\\u003C18 years\n* Receiving hemodialysis treatments for acute kidney injury\n* Receiving hemodialysis treatments for less than four weeks\n* Planned switch to peritoneal or home dialysis within next three months\n* Current or planned incremental hemodialysis (less than 3 treatments per week)\n* Current or planned intensive hemodialysis (four or more treatments per week)\n* Scheduled kidney transplantation\n* Major cardiovascular or bleeding event within previous 90 days\n* Receiving chemotherapy or radiation treatment for cancer\n* History of cirrhosis with ascites\n* Inability to complete 24-hour ambulatory blood pressure measurement\n* Wheelchair dependance or other inability to complete six-minute walk test\n* Pre-dialysis systolic blood pressure \\\u003C100 mmHg\n* Scheduled use of midodrine with hemodialysis treatments\n* History of non-adherence with dialysis treatments\n* Pregnancy\n* Institutionalized\n* Current or pending enrollment in hospice care\n* Inappropriate for enrollment based on investigator or nephrologist discretion","ALL","18 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"NA","Most patients who receive hemodialysis treatments have excess fluid in their body that has slowly built up over the course of kidney disease. This extra fluid is the main cause of high blood pressure in dialysis and leads to stress on the heart and lungs.that causes debilitating symptoms and frequent hospitalizations.\n\nThis trial will test whether a focused program of 4 or 8 weeks of extra ultrafiltration treatments can remove most of this extra fluid. We believe that getting rid of large amounts of extra fluid will result in sustained improvements in blood pressure and symptoms. Ultrafiltration is a gentler type of dialysis that removes fluid but does not clean the blood.",[26,27,28],"Fluid Accumulation","Blood Pressure Management","End Stage Renal Disease (ESRD)",[30,31,32,33,34,35,36,37],"ESRD","Volume overload","Fluid accumulation","End stage renal disease","Congestion","Chronic dialysis","Blood Pressure (High)","Blood pressure management","NOT_YET_RECRUITING","2026-06-03",{"date":41,"type":42},"2026-06-09","ACTUAL",{"date":44,"type":20},"2026-06",{"date":46,"type":20},"2030-11",{"name":48,"class":49},"University of Washington","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":57,"eligibilityCriteria":58,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":21,"phases":61,"briefSummary":63,"conditions":64,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":69,"lastUpdatePostDateStruct":70,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":50},"100633463","phase-3-stratified-blood-pressure-management-after-endovascular-treatment-for-acute-ischemic-stroke-100633463","NCT07527013","Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke","Stratified Blood Pressure Management After Endovascular Treatment for Acute Ischemic Stroke (RESCUE-BP)","RESCUE-BP","Inclusion Criteria:\n\n* Age ≥ 18 years；\n* Clinical diagnosis of acute ischemic stroke caused by anterior circulation large vessel occlusion (internal carotid artery or M1\u002FM2 segment of the middle cerebral artery)；\n* Received EVT (including direct EVT and bridging therapy) within 24 hours of symptom onset；\n* Baseline ASPECTS score ≥ 3；\n* Baseline NIHSS score ≥ 6；\n* Successful recanalization achieved post-procedure (defined as expanded Thrombolysis in Cerebral Infarction \\[eTICI\\] grade ≥ 2b50);\n* Two consecutive systolic blood pressure (SBP) measurements ≥ 150 mmHg within 3 hours post-recanalization (with a measurement interval of no less than 5 minutes)；\n* Able to complete randomization within 3 hours post-recanalization；\n* Informed consent signed by the patient or their legal representative.\n\nExclusion Criteria:\n\n* Pre-stroke mRS score \\> 1；\n* Comatose state (Glasgow Coma Scale \\[GCS\\] score \\\u003C 8);\n* Symptomatic intracerebral hemorrhage occurred before randomization;\n* Within the past 3 months, occurrence of acute ST-segment elevation myocardial infarction (MI), acute decompensated heart failure, QTc \\> 500 ms, hospitalization or involuntary coronary intervention due to acute coronary syndrome, MI, or cardiac arrest; or heart failure (New York Heart Association \\[NYHA\\] class III\u002FIV or left ventricular ejection fraction \\\u003C 35%); or known history of ventricular tachycardia;\n* History of severe renal insufficiency, acute renal failure, dialysis, or estimated glomerular filtration rate (eGFR) \\\u003C 20 ml\u002Fmin\u002F1.72m²;\n* History of severe hepatic disease, or Aspartate Aminotransferase (AST) and\u002For Alanine Aminotransferase (ALT) and\u002For Gamma-Glutamyl Transferase (GGT) ≥ 3×ULN and\u002For Total Bilirubin (TBIL) ≥ 2×ULN;\n* Aortic dissection, cervical artery dissection, or cerebral artery dissection; unruptured aortic aneurysm or cerebral aneurysm; or known arteriovenous malformation;\n* Comorbidities with a life expectancy \\\u003C 6 months (e.g., malignant tumors);\n* Pregnant or lactating women;\n* Participation in another clinical trial within the past 30 days;\n* Any clinical condition judged by the research team that might limit compliance with study procedures.",{"count":60,"type":20},544,[62],"PHASE3","The RESCUE-BP is a multi-centered, prospective, randomized, open label, blinded endpoint (PROBE) phase III trial. In patients with acute ischemic stroke who have undergone endovascular treatment and achieved successful recanalization, the evaluation will compare a stratified blood pressure management strategy based on the collateral circulation status with the guideline-recommended conventional blood pressure management strategy. Within each stratum, participants will be randomized in a 1:1 ratio to either the stratified blood pressure management strategy group or the guideline-recommended conventional blood pressure management group. The goal is to determine whether this can improve good functional outcomes at 90 days (90-day Modified Rankin Scale \\[mRS\\] score 0-2).\n\nThe study consists of four visits including the day of randomization, 24±4 hours after randomization, 7±1 days after randomization and 90±7 days after randomization. Demographic information, symptoms and signs, laboratory test, neuro-imaging assessment, neurological function rating scale will be recorded during the program.\n\nThe primary outcome is the modified Rankin Scale (mRS) score of 0 to 2 at 90±7 days after randomization. The primary safety outcome is the incidence of sICH within 24±4 hours after randomization.",[65,66,67,27,68],"Endovascular Therapy","Acute Ischaemic Stroke","Collateral Circulation","Prognosis","2026-04-17",{"date":71,"type":42},"2026-04-22",{"date":73,"type":20},"2026-06-01",{"date":75,"type":20},"2028-02-29",{"name":77,"class":49},"Beijing Tiantan Hospital",{"id":79,"slug":80,"hasResults":11,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":84,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":86,"maxAge":4,"enrollmentInfo":87,"targetDuration":4,"studyType":21,"phases":89,"briefSummary":90,"conditions":91,"keywords":94,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":5},"100584125","phase-3-noradrenaline-versus-standard-blood-pressure-management-for-perioperative-hypotension-in-non-cardiac-surgery-100584125","NCT06885268","Noradrenaline Versus Standard Blood Pressure Management for Perioperative Hypotension in Non-cardiac Surgery","The Effect of Noradrenaline Infusion Versus Standard Blood Pressure Management on Perioperative HYPotension in NOn-caRdiac Surgery HYP-NOR Trial","HYP-NOR","Inclusion Criteria:\n\n1. ≥45 years old\n2. Elective or accelerated\\* non-cardiac surgery expected to last ≥1 hour and requiring general, neuraxial, or combined general with neuraxial anesthesia\n3. Expected to stay overnight in the hospital after surgery\n4. Written informed consent to participate in the HYP-NOR Trial provided\n5. American Society of Anesthesiologists (ASA) physical status class II or higher.\n\nExclusion Criteria:\n\n1. Newly diagnosed, untreated, or uncontrolled hypertension -in two measurements on the day before surgery Systolic Blood Pressure (SBP) ≥180 mm Hg or Diastolic Blood Pressure (DBP) ≥110 mm Hg\n2. Persistent difference in recorded SBP between right and left upper limb \\>10 mm Hg\n3. Persistent atrial fibrillation\n4. Have a documented history of dementia\n5. Have language, vision, or hearing impairments that may compromise cognitive assessments\n6. Have a condition that precludes routine blood pressure management such as surgeon request for relative hypotension\n7. Receiving irreversible nonselective monoamine oxidase inhibitors (e.g. tranylcypromine, phenelzine) within 2 weeks preceding study enrolment\n8. The use of tricyclic antidepressants\n9. Have Prinzmetal angina\n10. Have contraindications to noradrenaline per clinician judgement\n11. Noradrenaline infusion started before surgery or plan to use continuous noradrenaline infusion throughout the procedure\n12. Treating physician (surgeon\u002Fanaesthetist) decides on the necessity of extended continuous hemodynamic monitoring during or after surgery\n13. Severe kidney disease (MDRD creatinine clearance \\\u003C15 mL\u002Fmin\u002F1.73m2) or renal replacement therapy\n14. End-stage heart failure: defined as NYHA Class IV - severe limitations in daily activity. Patients experience symptoms even while at rest. Mostly bedbound patients.\n15. Known severe liver disease: defined as the presence of liver cirrhosis or any of the symptoms of severe liver dysfunction: portal hypertension (esophageal varices, ascites), hepatocellular insufficiency (e.g., jaundice, hepatic encephalopathy) and coagulopathy (prolonged INR\u002FAPTT associated with known liver dysfunction).\n16. Emergency and urgent surgery defined as performed within 24 hours of sudden illness\u002Funplanned admission to hospital\n17. Have previously participated in the trial: patient already took a part in the HYP-NOR trial in the past\n18. Pregnant or breastfeeding women.","45 Years",{"count":88,"type":20},750,[62],"The effect of noradrenaline infusion versus standard blood pressure management on perioperative HYPotension in NOn-caRdiac surgery.\n\nThe study aims to determine whether perioperative noradrenaline infusion is superior to standard blood pressure management for the occurrence of perioperative hypotension.",[27,92,93],"Intraoperative Hypotension","Non-cardiac Surgery",[95,96,97],"hypotension","noradrenaline infusion","perioperative care","RECRUITING","2026-01-12",{"date":101,"type":42},"2026-01-14",{"date":103,"type":42},"2025-06-25",{"date":105,"type":20},"2027-06-30",{"name":107,"class":49},"Jagiellonian University",{"id":109,"slug":110,"hasResults":11,"nctId":111,"briefTitle":112,"officialTitle":113,"acronym":114,"eligibilityCriteria":115,"healthyVolunteers":116,"sex":117,"minAge":118,"maxAge":119,"enrollmentInfo":120,"targetDuration":4,"studyType":21,"phases":122,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":50},"100581069","impact-of-resistance-training-intensity-on-blood-pressure-100581069","NCT06845514","Impact of Resistance Training Intensity on Blood Pressure","High Blood Pressure and Effect of Acute Resistance Training: Influence of Different Load Intensities on Postexercise Hypotension and Ambulatory Blood Pressure in Aging Females","HEART","Inclusion Criteria:\n\n* aged 50 to 70 years;\n* absence of menstruation for 12 consecutive months;\n* normal-high resting blood pressure (120 ≤ Systolic ≤ 139 mmHg and 80 ≤ Diastolic ≤ 89 mmHg) or stage 1 hypertension (140 ≤ Systolic ≤ 159 mmHg or 90 \\\u003C Diastolic ≤ 99 mmHg);\n* physically inactive (\\\u003C 150 minutes of structured aerobic physical activity per week);\n* and not engaging in regular resistance exercise (≥ 2 sessions per week) for more than 3 months during the year.\n\nExclusion Criteria:\n\n* orthopedic limitations or other contraindications to resistance exercise;\n* scheduled surgery during the study;\n* unstable hypertension (≥ 160\u002F100 mmHg);\n* diagnosis of type 2 diabetes;\n* cardiovascular event in the past 6 months or sequelae preventing exercise;\n* and initiation of hormonal replacement therapy (\\\u003C 4 months) known to affect blood pressure.",true,"FEMALE","50 Years","70 Years",{"count":121,"type":20},36,[23],"The goal of the clinical trial is to understand the effect of two resistance training protocols employing different loading intensities (% of 1 repetition maximum; 1-RM), but with standardized effort intensity (2 repetitions in reserve; RIR) on post-exercise and ambulatory blood pressure in aging females.\n\nThe main questions it aims to answer are:\n\n* to examine the acute effects of low (50% 1-RM) and high (80% 1-RM) load intensity resistance exercise with a standardized high effort intensity on post-exercise hypotension and ambulatory blood pressure responses in aging females;\n* deepen the understanding of the mechanisms underlying acute reductions in blood pressure in response to resistance exercise performed at different load intensities. To this end, autonomic activity will be estimated alongside the measurement of central arterial compliance (i.e., carotid artery), and serum biomarkers of endothelial function;\n* document the affective valence and enjoyment associated with low (50% 1-RM) and high (80% 1-RM) load intensity resistance exercise when performed at a high perceived effort.\n\nResearchers will compare the effect of: 1) a low load (LL-RE) intensity protocol consisting of 3 sets of each exercise at 50% 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2); 2) high load (HL-RE) intensity protocol consisting of 3 sets of each exercise at 80% of 1-RM, performed until reaching a hard perceived effort intensity (i.e., RIR-2); 3) and a control condition (CON) consisting of a standardized non-fatiguing cognitive task.\n\nParticipants will participate in:\n\n* A preliminary assessment visit;\n* Two familiarization visits to validate the exercise prescriptions;\n* Three experimental visits (CON, LL-RE, HL-RE).",[27,125,126,127],"Blood Pressure Monitoring, Ambulatory","Blood Pressure, High","Blood Pressure",[129,130,131,132,133],"resistance training","ambulatory blood pressure","aging females","load intensity","perceived effort","2025-09-02",{"date":136,"type":42},"2025-09-09",{"date":138,"type":42},"2025-07-08",{"date":140,"type":20},"2028-12",{"name":142,"class":49},"Université de Sherbrooke",{"id":144,"slug":145,"hasResults":11,"nctId":146,"briefTitle":147,"officialTitle":148,"acronym":4,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":16,"minAge":118,"maxAge":150,"enrollmentInfo":151,"targetDuration":4,"studyType":21,"phases":153,"briefSummary":154,"conditions":155,"keywords":161,"overallStatus":98,"whyStopped":4,"lastUpdateSubmitDate":163,"lastUpdatePostDateStruct":164,"startDateStruct":166,"completionDateStruct":168,"leadSponsor":170,"locationsCount":50},"100378566","intraoperative-blood-pressure-management-and-dexamethasone-in-lung-cancer-surgery-100378566","NCT04209218","Intraoperative Blood Pressure Management and Dexamethasone in Lung Cancer Surgery","Impact of Intraoperative Blood Pressure Management and Dexamethasone on Patient's Outcomes After Lung Cancer Surgery: A 2 × 2 Factorial Randomized Controlled Trial","Inclusion Criteria:\n\n* Aged \\>50 years but \\\u003C90 years.\n* Diagnosed as resectable primary non-small cell lung cancer (stage IA-IIIA) and scheduled for radical surgery with an expected duration of \\>2 hours.\n* Agree to participate in this study and sign the informed consent.\n\nExclusion Criteria:\n\n* Clinical examinations suggest non-resectable lung cancer or patients scheduled for a biopsy surgery.\n* Recurrent or metastatic lung cancer.\n* History of cancer or complicated with cancer in other organs.\n* Long-term exposure to glucocorticoids or other immunosuppressant(s) due to autoimmune disease or organ transplantation.\n* Uncontrolled hypertension (systolic blood pressure \\>180 mmHg or diastolic blood pressure \\>110 mmHg); or requirement of vasopressors to maintain blood pressure.\n* Persistent atrial fibrillation, or acute cardiovascular events (acute coronary syndrome, stroke, or congestive heart failure) within 3 months.\n* Severe hepatic dysfunction (Child-Pugh C) or renal failure (requirement of renal replacement therapy).\n* Any other circumstances considered unsuitable for study participation by attending physicians or investigators.","90 Years",{"count":152,"type":20},1988,[23],"Surgery is the front-line therapy for non-small cell lung cancer (NSCLC) but postoperative complications remains high and patients' long-term outcome is still challenging. In addition to surgery, anesthetic management particularly intraoperative blood pressure management and use of dexamethasone may affect patients' early and long-term outcomes after surgery for NSCLC. This study aims to investigate the impact of intraoperative blood pressure management and dexamethasone administration on early and long-term outcomes in patients undergoing surgery for lung cancer.",[156,157,27,158,159,160],"Lung Cancer","Surgery","Dexamethasone","Overall Survival","Postoperative Complications",[156,162,27,158,159,160],"Radical Resection","2025-07-29",{"date":165,"type":42},"2025-07-31",{"date":167,"type":42},"2020-04-07",{"date":169,"type":20},"2029-12",{"name":171,"class":49},"Peking University First Hospital"]